Skip to main
ALKS
ALKS logo

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC demonstrates a positive outlook due to the promising quantitative analyses supporting alixorexton's potential in treating narcolepsy type 1 (NT1), enhancing confidence in product efficacy. Specifically, alixorexton achieved rapid normalization in the Epworth Sleepiness Scale (ESS) at week 2, indicating effective performance in key wakefulness measures. Furthermore, the durability of this response during the open-label extension period underscores the likelihood of sustained benefits for patients, reinforcing the company’s strong position in addressing unmet medical needs.

Bears say

Alkermes PLC's outlook appears negative due to inconsistent results from its investigational product alixorexton, which displayed variability in the weekly cataplexy rate (WCR) with statistical significance only achieved at the 6 mg dose. The mixed outcomes in patient-reported endpoints may lead to uncertainty regarding the product's effectiveness, potentially diminishing investor confidence. Additionally, the reliance on proprietary technologies and third-party collaborations raises concerns about the company's ability to consistently deliver on unmet medical needs in competitive therapeutic markets.

Alkermes (ALKS) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 12 analysts, Alkermes (ALKS) has a Buy consensus rating as of Oct 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.